FindTrial
Sign In

Development and validation of a CT-based radiomic signature to predict number of lymph node metastasis in pancreatic ductual adenocarcinoma

Development and validation of a CT-based radiomic signature to predict number of lymph node metastasis in pancreatic ductual adenocarcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035743
Enrollment
Unknown
Registered
2020-08-16
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic ductual adenocarcinoma

Interventions

Gold Standard:Clinical outcomes
Index test:CT-based&#32
radiomic&#32
signature&#32
to&#32
predict&#32
number&#32
of&#32
lymph&#32
node&#32
metastasis&#32
in&#32
pancreatic&#32
ductual&#32
adenocarcinoma.

Sponsors

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with pancreatic ductal adenocarcinoma confirmed by pathology and radical resection (pt1-3nxm0) from 2016 to 2019; 2. Patients with more than 16 lymph node dissections; 3. Patients who underwent preoperative abdominal enhanced CT within 2 weeks before operation.

Exclusion criteria

Exclusion criteria: 1. Patients with neoadjuvant therapy (including radiotherapy, chemotherapy or other treatments); 2. Patients who can't label the tumor on the image; 3. Patients with previous history of abdominal malignant tumor.

Design outcomes

Primary

MeasureTime frame
number of lymph node metastasis;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactJiang Yu

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

jiangyu890401@163.com+86 15121007316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026